Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma.
about
Development of coronary artery stenosis in a patient with metastatic renal cell carcinoma treated with sorafenibVascular endothelial growth factor inhibitors: investigational therapies for the treatment of psoriasisThe Role of Biomarkers in Decreasing Risk of Cardiac Toxicity after Cancer TherapyVascular Complications of Cancer ChemotherapyWhat links BRAF to the heart function? New insights from the cardiotoxicity of BRAF inhibitors in cancer treatmentGetting to the Heart of the Matter: An Overview of Cardiac Toxicity Related to Cancer TherapyCardiac toxicity in cancer survivorsCardiac effects of anticancer therapy in the elderlyThe emerging issue of cardiac dysfunction induced by antineoplastic angiogenesis inhibitorsTherapy management of cardiovascular adverse events in the context of targeted therapy for metastatic renal cell carcinomaUse of biomarkers for the assessment of chemotherapy-induced cardiac toxicity.Recent Advances on Pathophysiology, Diagnostic and Therapeutic Insights in Cardiac Dysfunction Induced by Antineoplastic DrugsCardiovascular toxicity of multi-tyrosine kinase inhibitors in advanced solid tumors: a population-based observational studyRobust Classification of Small-Molecule Mechanism of Action Using a Minimalist High-Content Microscopy Screen and Multidimensional Phenotypic Trajectory AnalysisDevelopment of sorafenib-related side effects in patients diagnosed with advanced hepatocellular carcinoma treated with sorafenib: a systematic-review and meta-analysis of the impact on survival.Chemotherapy-Induced Cardiotoxicity: Pathophysiology and PreventionExpert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging.Cancer therapy-induced cardiotoxicity: basic mechanisms and potential cardioprotective therapies.Cardiomyocyte PDGFR-beta signaling is an essential component of the mouse cardiac response to load-induced stress.High-throughput screening of tyrosine kinase inhibitor cardiotoxicity with human induced pluripotent stem cells.Phase I and pharmacokinetic study of sunitinib in pediatric patients with refractory solid tumors: a children's oncology group study.Cardiomyocyte autophagy and cancer chemotherapy.Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological preventionSorafenib cardiotoxicity increases mortality after myocardial infarction.Brain natriuretic peptide precursor (NT-pro-BNP) levels predict for clinical benefit to sunitinib treatment in patients with metastatic renal cell carcinomaUnderstanding and managing toxicities of vascular endothelial growth factor (VEGF) inhibitorsCardio-Oncology: Cancer Therapy-related Cardiovascular Complications in a Molecular Targeted Era: New Concepts and Perspectives.Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors.Cardiotoxicity of the anticancer therapeutic agent bortezomib.Management of side effects associated with sunitinib therapy for patients with renal cell carcinoma.New trial designs and potential therapies for pulmonary artery hypertension.Cardiovascular disease in adult survivors of childhood cancer.Dynamic contrast-enhanced magnetic resonance imaging of sunitinib-induced vascular changes to schedule chemotherapy in renal cell carcinoma xenograft tumors.Crosstalk between mitogen-activated protein kinases and mitochondria in cardiac diseases: therapeutic perspectivesThe utility of serum biomarkers to detect myocardial alterations induced by Imatinib in rats.Risk of treatment-related deaths with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a meta-analysis of 41 randomized controlled trials.Stem cell therapy and breast cancer treatment: review of stem cell research and potential therapeutic impact against cardiotoxicities due to breast cancer treatment.Principal long-term adverse effects of imatinib in patients with chronic myeloid leukemia in chronic phase.A phase 1 trial and pharmacokinetic study of cediranib, an orally bioavailable pan-vascular endothelial growth factor receptor inhibitor, in children and adolescents with refractory solid tumors.An update on cardio-oncology.
P2860
Q21261282-3B925E60-1AB0-4A07-A54F-EED4AF38CC83Q22305863-0E72C258-1005-4425-89F7-CC6DE7099CEBQ26743433-6053E98C-86EE-4294-AB2B-6CACE56A5BA6Q26766269-5AFF3FED-29CC-4D08-B67D-5D3F6E7CD203Q26782585-FF82C5C1-5982-4E5B-A432-95AFB3B24F4BQ26797138-CA49DB1D-27E1-41AE-8461-1223E9BA48FFQ26851957-F837F6DE-AEAF-4703-9EFD-934B8E168C21Q26863244-AC246C18-60DB-4347-8A9F-1AA5B58BF528Q27011540-9122CC0A-EB6D-438C-819F-23EEF74FC630Q27013665-0B4A2CC9-EE3D-41F5-80E2-487FD976F94DQ27027354-B72C26A4-B88B-46FE-B7AF-D993616D3F95Q28087776-8C077E61-2CFE-45E4-99D6-ECC4CE63979CQ28545130-84BD89B6-4F9F-45C8-8D1C-FB44F51E80B5Q28550236-88187413-BAB6-4F6D-8CD3-75A281D1129DQ30240748-115284CA-8BD3-4AA1-B844-DA055A960E56Q30399577-85121AF4-FC43-4123-86D2-A0B820819549Q30401812-4BBBAD26-1D2B-483E-9411-18A25E4FB31DQ30426853-E1D69759-1223-4AFD-B6FD-248D3593F048Q30492863-B7CDBA74-8780-4E62-93DC-7771D2BF90FEQ30847302-DB89FCAD-A2AE-421C-8BC6-DACA0507EB31Q33395853-ADF1EE69-4330-44CB-B845-2678783FACBEQ33573823-B2E746A7-D84A-47BE-AECA-17EEBBAB5A3EQ33574045-247AD3BA-983B-4878-B676-A004195A47EAQ33681995-964A9518-BBF9-4BCD-8270-5BDE0959E7D0Q33692402-E7F31957-3060-4C51-864B-0A49FB9EB364Q33698419-E8BDF93F-72E3-4DC1-AB05-C3A3E2232956Q33807542-73D5187B-E508-40CA-8009-3CD50EE78B05Q33828690-3CF43F05-4FC8-436A-B704-AEBCBBE982F9Q33882390-97310AC1-E6B7-43DB-9082-FDAAEB662526Q33916002-4BD4AF41-5DFE-4D6B-8490-12B571651C75Q33982467-012258AD-B0E9-464D-B081-A1F15C5E102BQ34042984-E9622E92-84CC-48D9-B91A-726F67831E32Q34111200-A96696EE-1041-456F-8A46-0E65350A87D9Q34289211-1C427A34-73ED-41B5-8017-0202B496EB39Q34292469-30B82BE4-8192-4F47-9803-2C4CD2B76178Q34352627-88E7E7F6-93EF-4841-93AE-150BB3A4872CQ34441749-8A02E55D-8D08-4B60-9720-E6EC5D1A6971Q34443523-5C8A5EB2-32DB-4B6C-8327-0E5972A4306BQ34488671-E1790578-43AC-48E8-8A63-25409FE95164Q34650059-41F505F9-68E4-4181-9A1A-B5557C8BAEFF
P2860
Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
Cardiac toxicity of sunitinib ...... tastatic renal cell carcinoma.
@en
Cardiac toxicity of sunitinib ...... tastatic renal cell carcinoma.
@nl
type
label
Cardiac toxicity of sunitinib ...... tastatic renal cell carcinoma.
@en
Cardiac toxicity of sunitinib ...... tastatic renal cell carcinoma.
@nl
prefLabel
Cardiac toxicity of sunitinib ...... tastatic renal cell carcinoma.
@en
Cardiac toxicity of sunitinib ...... tastatic renal cell carcinoma.
@nl
P2093
P356
P1476
Cardiac toxicity of sunitinib ...... tastatic renal cell carcinoma.
@en
P2093
Andja Bojic
Christoph C Zielinski
Christoph Schukro
Herwig Schmidinger
Manuela Schmidinger
Marija Bojic
Marquerite Ruhsam
Michael Hejna
Ursula M Vogl
P304
P356
10.1200/JCO.2007.15.6331
P407
P577
2008-10-06T00:00:00Z